KEYTRUDA® receives additional FDA approval
On August 12th, 2021
The FDA has approved KEYTRUDA® (pembrolizumab) Injection 100 mg for the treatment of patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.
Recommended Dosage for High-Risk Early-Stage TNBC
Please refer to the Prescribing Information for KEYTRUDA for information about dosing for high-risk early-stage TNBC.
Before prescribing KEYTRUDA® (pembrolizumab), please read the Prescribing Information. The Medication Guide also is available.
The FDA has approved KEYTRUDA® (pembrolizumab) Injection 100 mg for the treatment of patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.
Recommended Dosage for High-Risk Early-Stage TNBC
Please refer to the Prescribing Information for KEYTRUDA for information about dosing for high-risk early-stage TNBC.
Before prescribing KEYTRUDA® (pembrolizumab), please read the Prescribing Information. The Medication Guide also is available.
No comments have been posted yet.